Imagion Biosystems Ltd: 2023 Annual Report to shareholders
Imagion Biosystems CEO Resigns
Imagion Biosystems (ASX:IBX) said Isaac Bright resigned as chief executive, effective Monday, to pursue other opportunities. Chair Bob Proulx will resume operating responsibilities as interim executiv
Imagion Biosystems Validates Safety, Feasibility of Breast Cancer Imaging Agent in Phase One Trial; Shares Rise 7%
Imagion Biosystems (ASX:IBX) validated the safety and clinical feasibility of the MagSense HER2 imaging agent following results from a phase one clinical trial. The study met its safety and tolerabili
Argenica Therapeutics Appoints Nonexecutive Chair
Argenica Therapeutics (ASX:AGN) appointed Dianne Angus as nonexecutive chair, effective Dec. 1, succeeding Geoff Pocock. Angus serves as director of Neuren Pharmaceuticals (ASX:NEU), Cyclopharm (ASX:C
Imagion Biosystems Completes Phase 1 Imaging Agent Study
Imagion Biosystems (ASX:IBX) completed its imaging agent phase 1 study for MagSense to help detect human epidermal growth factor receptor 2-positive tumors, according to a Wednesday filing. The trial
Imagion Biosystems Secures AU$3.5 Million R&D Tax Rebate for Fiscal Year 2022
Imagion Biosystems (ASX:IBX) secured a AU$3.5 million rebate for the fiscal year ended June 30, 2022 from the Australian government's research and development tax incentive scheme. The refund is highe
Stocks of the Hour: Sayona Mining, Tamboran Resources, Imagion Biosystems
Sayona Mining (ASX:SYA) announced that their preliminary technical study at their NAL lithium carbonate plant study produces an NPV of A$3.2bn. Sayona's Managing Director, Brett Lynch commented: "Sign
Imagion Biosystems (ASX:IBX) Reaches Enrolment Targets Ahead of Cancer Study
Imagion Biosystems (ASX:IBX) Flags Big R&D Spending Over 2022
Here's Why We're A Bit Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Situation
Imagion Biosystems (ASX:IBX) Accelerates MagSense Development Following Independent Review
Imagion Biosystems (ASX:IBX) Advances MagSense Phase One Study in December Quarter
Imagion Biosystems (ASX:IBX) Reports "Positive" First MagSense Breast Cancer Clinical Data
No Data